Drug Updates

Dr. Kaufman is a freelance medical writer based in New York City and a clinical pharmacist at New York Downtown Hospital.

References

1. Roxro announces FDA approval of Sprix. www.sprix.com/docs/SPRIX-approval-press-release.pdf. Published May 17, 2010. Accessed May 24, 2010.
2. Roy C. GlaxoSmithKline, Human Genome Sciences’ lupus drug Benlysta fails secondary endpoint in phase III study. www.firstwordplus.com/Fws.do?articleid=EC8EA1A513274EDA94E3A541C6BE18A2&logRowId=361010. Published April 20, 2010. Accessed May 24, 2010.
3. Dennis M. FDA staff question cardiovascular risk of NicOx’s naproxcinod ahead of meeting. www.firstwordplus.com/Fws.do?articleid=215EE4F655E549B7BDF7E7080D16DF8E&logRowId=364007. Published May 11, 2010. Accessed May 24, 2010.
4. Dennis M. Roche, Biogen Idec halt development of ocrelizumab for rheumatoid arthritis. www.firstwordplus.com/Fws.do?articleid=AB3879AE22394F708E179A40E6E006F6&logRowId=365165. Published May 19, 2010. Accessed May 24, 2010.
5. Roche and Biogen Idec decide to suspend Ocrelizumab treatment-Rheumatoid Arthritis development programme on hold. www.roche.com/media/media_releases/med-cor-2010-03-08.htm. Published March 8, 2010. Accessed May 24, 2010.
6. Dane L. FDA advisory panel votes not to recommend Acura, King’s Acurox. www.firstwordplus.com/Fws.do?articleid=A2AACAE25AF042CB86175DCC0D39CE16&logRowId=361174. Published April 22, 2010. Accessed May 24, 2010.
7. U.S. Food and Drug Administration. Ultram (tramadol hydrochloride), Ultracet (tramadol hydrochloride/acetaminophen): Label change. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm213264.htm. Published May 25, 2010. Accessed May 26, 2010.
8. U.S. Food and Drug Administration. Important drug warning. www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM213265.pdf. Published March 2010. Accessed May 26, 2010.
9. Hayward K, Wallace CA. Recent development in anti-rheumatic drugs in pediatrics: Treatment of juvenile idiopathic arthritis. Arthritis Res Ther. 2009;11:216.
10. Hoffart C, Sherry DD. More aggressive treatment for juvenile idiopathic arthritis. J Musculoskel Med. 2010;27:106-108.
11. Enbrel label. www.accessdata.fda.gov/drugsatfda_docs/label/2008/103795s5359lbl.pdf. Published June 23, 2008. Accessed May 26, 2010.
12. U.S. Food and Drug Administration. Humira approval letter for juvenile idiopathic arthritis. www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/125057s114ltr.pdf. Published February 21, 2008. Accessed May 26, 2010.
13. Humira label with new indication for JIA. www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s114lbl.pdf. Published February 2008. Accessed May 26, 2010.
14. Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56:3096-3106.
15. Orencia label. www.accessdata.fda.gov/drugsatfda_docs/label/2009/125118s0086lbl.pdf. Published August 25, 2009. Accessed May 26, 2010
16. Single-dose study to assess efficacy of canakinumab (ACZ885) in patients with active systemic juvenile idiopathic arthritis (SJIA) (β-SPECIFIC 1). www.clinicaltrials.gov/ct2/show/NCT00886769?term=acz885+and+sjia&rank=2NCT00886769. Published April 22, 2009. Updated March 24, 2010. Accessed May 26, 2010.
17. Novartis set to sustain its leading global position in oncology with portfolio targeting various tumors and life-threatening diseases. www.novartis.com/newsroom/media-releases/en/2009/1359994.shtml. Published December 9, 2009. Accessed May 26, 2010.
18. First quarter 2010 results: Novartis investors presentation. www.novartis.com/downloads/investors/sales-results/q1-2010-investor-presentation.pdf. Published April 20, 2010. Accessed May 26, 2010.
19. UCB’s new development pipeline. www.ucb.com/rd/pipeline/new-development. Published 2010. Accessed May 26, 2010.
20. Cimzia label. www.accessdata.fda.gov/drugsatfda_docs/label/2009/125160s092lbl.pdf. Published November 18, 2009. Accessed May 26, 2010.
21. Roche Pharmaceuticals pipeline. www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm. Published April 16, 2010. Accessed May 26, 2010.
22. A study of tocilizumab in patients with active systemic juvenile idiopathic arthritis. www.clinicaltrials.gov/ct2/show/NCT00642460?term=tocilizumab+and+JIA&rank=2. Published March 19, 2008. Updated May 25, 2010. Accessed May 26, 2010.
23. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861-1874.